ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.499,93
-0,54%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08976
-0,02%
Bitcoin
63.685,77
-1,80%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
15/09/202313h42Business WireAstraZeneca s'engage à hauteur de 100 mio. £ pour promouvoir le chauffage propre et améliorer l'efficacité énergétique de ses sites au Royaume-UniNASDAQ:AZNAstraZeneca PLC
14/09/202308h00Business WireAstraZeneca advances UK clean heat and energy efficiencies with £100m commitmentNASDAQ:AZNAstraZeneca PLC
12/09/202313h29IH Market NewsTuesday’s Wall Street Highlights: Apple, Acelyrin, WestRock, Oracle, UPS, and moreNASDAQ:AZNAstraZeneca PLC
11/09/202319h48Dow Jones NewsAstraZeneca Phase 3 Trial for Rare Vasculitis Treatment Meets Primary EndpointNASDAQ:AZNAstraZeneca PLC
11/09/202318h58Business WireFASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)NASDAQ:AZNAstraZeneca PLC
11/09/202317h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
11/09/202313h05Business WireTAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III TrialNASDAQ:AZNAstraZeneca PLC
11/09/202313h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II TrialNASDAQ:AZNAstraZeneca PLC
11/09/202312h49IH Market NewsAstraZeneca Says Lung Cancer Drug Showed Durable Tumor Response in Mid-Stage TrialNASDAQ:AZNAstraZeneca PLC
11/09/202308h55Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control RatesNASDAQ:AZNAstraZeneca PLC
06/09/202312h59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
06/09/202308h51Dow Jones NewsAstraZeneca Says FDA Has Requested Improvements to Ultomiris's Risk EvaluationNASDAQ:AZNAstraZeneca PLC
04/09/202308h45Dow Jones NewsAstraZeneca's Calquence Product Approved in China for Leukaemia TreatmentNASDAQ:AZNAstraZeneca PLC
01/09/202316h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
25/08/202313h57Dow Jones NewsAstraZeneca Files Legal Challenge to Some Drug-Price Provisions of IRANASDAQ:AZNAstraZeneca PLC
25/08/202313h10Business WireAstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patientsNASDAQ:AZNAstraZeneca PLC
24/08/202308h58Dow Jones NewsAstraZeneca Prostate Cancer, Generalized Myasthenia Gravis Treatments Get Approval in JapanNASDAQ:AZNAstraZeneca PLC
16/08/202316h00Business WireAstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030NASDAQ:AZNAstraZeneca PLC
09/08/202312h30Dow Jones NewsStatkraft Strikes Swedish Wind Power Purchase Deal with AstraZenecaNASDAQ:AZNAstraZeneca PLC
04/08/202309h17Dow Jones NewsSanofi, AstraZeneca RSV Treatment for Infants Gets U.S. CDC Panel RecommendationNASDAQ:AZNAstraZeneca PLC
01/08/202318h23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
28/07/202314h46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
28/07/202313h41IH Market NewsFriday’s Wall Street Highlights: AMD, Intel, First Solar, Sleep Number, Roku, P&G, and moreNASDAQ:AZNAstraZeneca PLC
28/07/202312h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
28/07/202311h37Dow Jones NewsTrending: AstraZeneca Shares Rise on Significant Sales and Earnings OutperformanceNASDAQ:AZNAstraZeneca PLC
28/07/202310h54KR Market News알렉시온, 화이자 유전자 치료제를 10억 달러 인수 합의NASDAQ:AZNAstraZeneca PLC
28/07/202310h34Dow Jones NewsAstraZeneca Shares Rise After 2Q Revenue, Earnings Beat Market Views -- UpdateNASDAQ:AZNAstraZeneca PLC
28/07/202309h44KR Market News아스트라제네카, 항암제 수요로 2분기 결과 예상치 상회NASDAQ:AZNAstraZeneca PLC
28/07/202309h10Dow Jones NewsAstraZeneca's Alexion to Buy Gene Therapies Portfolio for Up to $1 Billion From PfizerNASDAQ:AZNAstraZeneca PLC
28/07/202309h03Dow Jones NewsAstraZeneca 2Q Net Profit Rose But Missed Forecasts; Backs GuidanceNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

PM
XAUUSD
Gold vs US Dollar
FX
EURGBP
Euro vs Sterling
NASDAQ
AMZN
Amazon.com
CCOM
US100
US Tech 100
COIN
SOLUSD
Solana
NYSE
MRK
Merck
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
DBI
SDXP
SDAX
TG
BAS
BASF
COIN
ETHUSD
Ethereum
TG
RHM
Rheinmetall
NASDAQ
NVDA
NVIDIA
CCOM
SILVER
SILVER
TG
MBG
MercedesBenz
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten